Volatile Organic Compounds in Irritable Bowel Syndrome: Microbial Insights into Gut-Brain Dynamics and Clinical Applications.

IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Digestion Pub Date : 2025-09-04 DOI:10.1159/000548310
Dinh Chuong Nguyen, Sutep Gonlachanvit, Thanikan Sukaram, Tanisa Patcharatrakul
{"title":"Volatile Organic Compounds in Irritable Bowel Syndrome: Microbial Insights into Gut-Brain Dynamics and Clinical Applications.","authors":"Dinh Chuong Nguyen, Sutep Gonlachanvit, Thanikan Sukaram, Tanisa Patcharatrakul","doi":"10.1159/000548310","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Irritable Bowel Syndrome (IBS) affects 4.1% of the global population, posing a significant healthcare challenge due to its complex pathophysiology and limited treatment options. Gut microbiota-derived volatile organic compounds (VOCs) are increasingly recognized as key players in IBS, with the potential for non-invasive diagnostics and personalized management.</p><p><strong>Summary: </strong>This review examines VOCs-such as short-chain fatty acids (SCFAs), hydrocarbons, and alcohols-as microbial metabolites influencing IBS through gut barrier function, inflammation, motility, and gut-brain signaling. Cross-sectional studies highlight the diagnostic accuracy of VOCs (Area Under the Curve (AUC) 0.76-0.99) in distinguishing IBS from healthy controls (HC) and conditions like inflammatory bowel disease (IBD), while longitudinal studies underscore their utility in predicting and reflecting microbial changes to microbiota-targeted therapies. Despite this promise, variability in study designs, methodological inconsistencies, and confounding factors hinder clinical translation.</p><p><strong>Key messages: </strong>VOCs illuminate the microbial underpinnings of IBS and its gut-brain interactions, offering a pathway to precise diagnosis and treatment stratification. However, their full potential awaits standardized sampling, analytical protocols, and robust clinical trials to ensure reliability and applicability in IBS care.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-14"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Irritable Bowel Syndrome (IBS) affects 4.1% of the global population, posing a significant healthcare challenge due to its complex pathophysiology and limited treatment options. Gut microbiota-derived volatile organic compounds (VOCs) are increasingly recognized as key players in IBS, with the potential for non-invasive diagnostics and personalized management.

Summary: This review examines VOCs-such as short-chain fatty acids (SCFAs), hydrocarbons, and alcohols-as microbial metabolites influencing IBS through gut barrier function, inflammation, motility, and gut-brain signaling. Cross-sectional studies highlight the diagnostic accuracy of VOCs (Area Under the Curve (AUC) 0.76-0.99) in distinguishing IBS from healthy controls (HC) and conditions like inflammatory bowel disease (IBD), while longitudinal studies underscore their utility in predicting and reflecting microbial changes to microbiota-targeted therapies. Despite this promise, variability in study designs, methodological inconsistencies, and confounding factors hinder clinical translation.

Key messages: VOCs illuminate the microbial underpinnings of IBS and its gut-brain interactions, offering a pathway to precise diagnosis and treatment stratification. However, their full potential awaits standardized sampling, analytical protocols, and robust clinical trials to ensure reliability and applicability in IBS care.

挥发性有机化合物在肠易激综合征:微生物洞察肠脑动力学和临床应用。
背景:肠易激综合征(IBS)影响全球4.1%的人口,由于其复杂的病理生理和有限的治疗选择,构成了重大的医疗挑战。肠道微生物衍生的挥发性有机化合物(VOCs)越来越被认为是肠易激综合征的关键因素,具有非侵入性诊断和个性化管理的潜力。摘要:本文综述了挥发性有机化合物,如短链脂肪酸(SCFAs)、碳氢化合物和酒精,作为微生物代谢产物,通过肠道屏障功能、炎症、运动和肠-脑信号传导影响肠易激综合征。横断面研究强调了VOCs(曲线下面积(AUC) 0.76-0.99)在区分IBS与健康对照(HC)和炎症性肠病(IBD)等疾病方面的诊断准确性,而纵向研究强调了它们在预测和反映微生物群靶向治疗的微生物变化方面的效用。尽管有这样的希望,但研究设计的可变性、方法的不一致性和混杂因素阻碍了临床转化。关键信息:挥发性有机化合物阐明了肠易激综合征及其肠脑相互作用的微生物基础,为精确诊断和分层治疗提供了途径。然而,它们的全部潜力需要标准化的采样、分析方案和强大的临床试验来确保IBS治疗的可靠性和适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Digestion
Digestion 医学-胃肠肝病学
CiteScore
7.90
自引率
0.00%
发文量
39
审稿时长
6-12 weeks
期刊介绍: ''Digestion'' concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on Stomach/Esophagus, Bowel, Neuro-Gastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal''s coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信